ArticleJCI insight2022

Bamlanivimab therapy for acute COVID-19 does not blunt SARS-CoV-2-specific memory T cell responses.

Sydney I Ramirez et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.